Brown, PC
Main Menu
Schedule Your Initial Consultation:
View Our Practice Areas

Pfizer to Save While Shareholders Might Pay More Tax

Although Pfizer Inc. will be saving hundreds of millions of dollars in annual taxes by buying AstraZeneca, Pfizer's stockholders could end up paying more tax. The trigger is unfamiliar U.S. tax regulations that are initiated in a purchase of an overseas entity and relocation of a U.S. business.

According to these rules, the 6.38 billion common shares that Pfizer has distributed to shareholders will be subject to capital gain tax on the increase in value when converted after the companies merge.

According to The Wall Street Journal, Pfizer shares closed at $29.17 on May 8, up 15 cents in New York Stock Exchange trading. AstraZeneca closed at £47.13, up 82 pence, on the London Stock Exchange.

Pfizer has been attempting to buy the British-owned competitor since November and if they can please AstraZeneca's shareholders, the two companies would create the largest pharmaceutical company in the world. The newly merged company would move their headquarters to the U.K. because of the lower corporate taxes. Pfizer's estimated annual savings could be up to $1 billion in taxes alone if this deal goes through.

Source: Rockoff, Jonathan D. and Saunders, Laura, "Pfizer Holders Could Face Tax Hit in a Deal for AstraZeneca," The Wall Street Journal, May 8, 2014.

No Comments

Leave a comment
Comment Information
Print this Page
Email Us For A Response
Set Up An Initial Consultation Now: 888-870-0025

Work Directly With Us

Bold labels are required.

Contact Information

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.


Privacy Policy